Rockville-The Food and Drug Administration has given the go-ahead to the new cosmetic filler, Radiesse, to treat chronic facial lipoatrophy, otherwise called fat loss, occurring in patients with AIDS or HIV. This calcium based treatment, is found to assist in the manufacture of collagen.
To ascertain the potential benefits of this filler, FDA embarked on a study of 100 HIV patients suffering facial lipoatrophy. The patients were given a shot of Radiesse and re-examined after six months. The evaluation revealed that 78% of the patients needed minimal fine tuning, yet not more than three injections.
The only side-effects which showed up were short-term inflammation, pain and reddening of the skin.